A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood

PHASE1CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

August 7, 2023

Primary Completion Date

March 14, 2025

Study Completion Date

March 14, 2025

Conditions
Healthy VolunteersDyslipidaemia
Interventions
DRUG

NNC0491-6075

NNC0491-6075 will be administered as a subcutaneous injection in a skinfold in the abdomen or intravenously into a vein in the wrist, elbow, or the back of the hand.

DRUG

Placebo

Placebo matched to NNC0491-6075 will be administered as a subcutaneous injection in a skinfold in the abdomen or intravenously into a vein in the wrist, elbow, or the back of the hand.

Trial Locations (1)

90630

Altasciences Clinical LA, Inc., Cypress

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY